Core Viewpoint - Fuxiang Pharmaceutical (300497) anticipates significant improvement in its financial performance for 2025, projecting revenue between 1.15 billion to 1.25 billion yuan and a reduced net loss of 39 million to 57 million yuan compared to 2024, with a turnaround expected in Q4 2025 [1] Group 1: Business Segments - The company has been deeply involved in the pharmaceutical intermediates and active pharmaceutical ingredients sectors, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein businesses [1] - The lithium battery electrolyte additive segment is expected to be the main driver of revenue growth in 2025, benefiting from rising demand in the power battery and energy storage markets [1] - The average price of battery-grade VC has increased over 200% since the low point in September 2025, reflecting a tight supply-demand balance in the industry [2] Group 2: Financial Performance - Fuxiang Pharmaceutical has leveraged its scale production capacity and cost control advantages to benefit from the current price increase cycle, resulting in significant improvements in product shipment volume, sales revenue, and gross margin [2] - The pharmaceutical manufacturing segment has seen a reduction in the price of key raw materials, which has alleviated cost pressures and improved gross margins year-on-year [2] - The company has reduced asset impairment provisions, enhancing asset value stability as profitability improves in both its new energy and pharmaceutical businesses [2] Group 3: Future Growth Potential - The synthetic biology microbial protein business has achieved critical breakthroughs in 2025, with multiple certifications obtained, paving the way for compliance from research to large-scale production [3] - Although the microbial protein business is expected to contribute limited revenue in 2025, it is anticipated to become a core profit growth point as production capacity is released and market expansion progresses [3] - The company aims to consolidate its market position in pharmaceuticals, capitalize on price increases in the new energy sector, and accelerate the construction and market deployment of its microbial protein project to drive high-quality development [3]